The DOI matches its Crossref record; 26 of the 27 references it cites were found in a registry or an index; none of the 14 sources its claims cite is checked for support yet.
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Open accessAbstract
The somatic mutations in cytosolic isocitrate dehydrogenase 1 (IDH1) observed in gliomas can lead to the production of 2-hydroxyglutarate (2HG). Here, we report that tumor 2HG is elevated in a high percentage of patients with cytogenetically normal acute myeloid leukemia (AML). Surprisingly, less than half of cases with elevated 2HG possessed IDH1 mutations. The remaining cases with elevated 2HG had mutations in IDH2, the mitochondrial homolog of IDH1. These data demonstrate that a shared feature of all cancer-associated IDH mutations is production of the oncometabolite 2HG. Furthermore, AML patients with IDH mutations display a significantly reduced number of other well characterized AML-associated mutations and/or associated chromosomal abnormalities, potentially implicating IDH mutation in a distinct mechanism of AML pathogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
39 Own result · 18 Own interpretation · 13 Not checked yet · 8 Own method · 7 No basis given
In the paper
“There is a marked difference in the enzymatic rate of isocitrate-dependent NADPH production by the wild-type proteins and α-ketoglutarate-dependent NADPH consumption by both IDH1 and IDH2 mutants (Figure 2 and Dang et al., 2009).”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > DISCUSSION > Maintaining at least one IDH1 and IDH2 wild-type allele may be essential for transformed cells
What the sources say
- Not checked yetcites Dang et al., 2009 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“None of the IDH2-mutated samples were found to also have somatic mutations in Flt-3, NPM1, or ASXL1”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > IDH2 mutations are more common than IDH1 mutations in AML
plainn = 78- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IDH2 siRNA treated cells displayed a significant reduction in levels of citrate +5”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > IDH2 is critical for proliferating cells and contributes to the conversion of α-ketoglutarate into citrate in the mitochondria
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“2HG production is a shared feature of heterozygous mutations in either cytosolic IDH1 or mitochondrial IDH2.”
- Also stated in: § 2HG as an onco-metabolite · plain
“All IDH mutations reported to date share the neomorphic ability to produce high levels of tumor 2HG.”
- Also stated in: § Liquid chromatography-mass spectrometry (LC-MS) · plain
“Here we report that the common feature of IDH1 and IDH2 mutations observed in AML and glioma is the acquisition of an enzymatic activity not shared by either wild-type enzyme.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > DISCUSSION > Maintaining at least one IDH1 and IDH2 wild-type allele may be essential for transformed cells
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § 2HG as an onco-metabolite · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we noted a trend towards improved survival in patients who presented with IDH2 mutations (p=0.08, Figure S2B)”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > IDH2 mutations are more common than IDH1 mutations in AML
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All samples displaying a signal ratio for 2HG/glutamate > 1% had either an IDH1 or IDH2 mutation”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > 2HG can be used as a screening test for neomorphic IDH mutants
plaincorrelationaln = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“extracts from cells expressing the R172K mutant IDH2 did not display isocitrate-dependent NADPH production above the levels observed in extracts from vector-transfected cells”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > Mutation of IDH2 R172K enhances α-ketoglutarate-dependent NADPH consumption
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“none of the samples with a 2HG/glutamate signal ratio ≤ 1% had an IDH mutation”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > 2HG can be used as a screening test for neomorphic IDH mutants
plainn = 18- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IDH2 R172K expressing cells were found to have an approximately 100-fold increase in the intracellular levels of 2HG compared with the levels detected in vector-transfected and IDH2 wild-type overexpressing cells”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > Mutation of IDH2 R172K results in elevated 2HG levels
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“despite the reduced ability to bind isocitrate, the R140Q mutant IDH2 is predicted to maintain its ability to bind and orient α-ketoglutarate in the active site”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > 2HG can be used as a screening test for neomorphic IDH mutants
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- It may state two separate claims as one. 10
- Probably not a substantial claim. 17
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“In addition, it appears that both wild-type IDH1 and IDH2 can play positive and non-redundant roles in cell proliferation.”
- Also stated in: § Liquid chromatography-mass spectrometry (LC-MS) · plain
“Both wild-type IDH1 and IDH2 are required for cell proliferation.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > DISCUSSION > Maintaining at least one IDH1 and IDH2 wild-type allele may be essential for transformed cells
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Also stated in: § Liquid chromatography-mass spectrometry (LC-MS) · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While IDH1 mutations were found in 7.7% of samples in this analysis (6/78), twice as many mutations were detected in IDH2, at a frequency of 15.4% (12/78, p<0.05)”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > IDH2 mutations are more common than IDH1 mutations in AML
plainn = 78 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“IDH2 mutations are more common than IDH1 mutations in AML”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > IDH2 mutations are more common than IDH1 mutations in AML
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“when cells were treated with one of two independent siRNAs against IDH3, there was a reproducible increase in citrate +5, while citrate +4 was unchanged”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > IDH2 is critical for proliferating cells and contributes to the conversion of α-ketoglutarate into citrate in the mitochondria
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Overall, IDH2 mutations appear more common than IDH1 mutations in AML.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > EXPERIMENTAL PROCEDURES > Liquid chromatography-mass spectrometry (LC-MS)
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Mutations in human cytosolic isocitrate dehydrogenase I (IDH1) occur somatically in >70% of grade II-III gliomas and secondary glioblastomas, and in 8.5% of acute myeloid leukemias (AML)”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > INTRODUCTION
What the sources say
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“These IDH1 R132 mutations were observed in 8.5% of AML patients studied, and a significantly higher percentage of mutation was observed in the subset of patients whose tumors lacked cytogenetic abnormalities”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > INTRODUCTION
What the sources say
- Not checked yetcites Mardis et al., 2009 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“cancer-associated IDH1 R132 mutants display a loss-of-function for the use of isocitrate as substrate, with a concomitant gain-of-function for the reduction of α-ketoglutarate to 2HG”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > IDH2 is mutated in AML
What the sources say
- Not checked yetcites Dang et al., 2009 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data support a role for IDH2 and not IDH3 in the conversion of α-ketoglutarate into citrate by reductive carboxylation in the mitochondria”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > RESULTS > IDH2 is critical for proliferating cells and contributes to the conversion of α-ketoglutarate into citrate in the mitochondria
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“The R132H IDH1 mutation observed in gliomas was found to display a gain of function for the NADPH-dependent reduction of α-ketoglutarate to R(-)-2-hydroxyglutarate (2HG)”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > INTRODUCTION
What the sources say
- Not checked yetcites Dang et al., 2009 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“After redissolving samples in deionized water, citrate was detected on two different LC-MS approaches, both of which gave comparable results.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > EXPERIMENTAL PROCEDURES > Liquid chromatography-mass spectrometry (LC-MS)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Human IDH2 has 97% homology with pig IDH2, and none of the 13 residues that are different (out of 418 total, excluding the N-terminal mitochondrial signal sequence) are found in the active site.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > EXPERIMENTAL PROCEDURES > Structural modeling
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While the exact role of wild-type IDH2 in supporting cell growth will require further investigation, this requirement correlates with the ability of IDH2 to contribute to the conversion of α-ketoglutarate into citrate via a pathway of reductive carboxylation in the mitochondria of proliferating cells.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > DISCUSSION > Maintaining at least one IDH1 and IDH2 wild-type allele may be essential for transformed cells
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For all experiments, OD340 changes in assay buffer lacking lysate protein were measured and subsequently subtracted from the OD340 changes measured in lysate replicates to arrive at final values.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > EXPERIMENTAL PROCEDURES > Cell lysate based enzyme assays
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Actin antibody (Santa Cruz, sc1616) was also used to assess equal protein loading of Western blots.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > EXPERIMENTAL PROCEDURES > Western blot
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Isotopomer distributions were simultaneously corrected for naturally occurring heavy isotopes of all elements in each mass fragment using a correction matrix as previously described (Weckwerth, 2007).”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > EXPERIMENTAL PROCEDURES > Gas chromatography-mass spectrometry (GC-MS) analysis
What the sources say
- Not checked yetcites Weckwerth, 2007
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Identification of the 2HG metabolite peak was confirmed using standards obtained from Sigma.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > EXPERIMENTAL PROCEDURES > Gas chromatography-mass spectrometry (GC-MS) analysis
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“A PDB structure of pig IDH2 is available, with isocitrate in the active site (1LWD) (Ceccarelli et al., 2002).”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > EXPERIMENTAL PROCEDURES > Structural modeling
What the sources say
- Not checked yetcites Ceccarelli et al., 2002 source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“for samples with less than 70% blasts flow cytometric sorting (FACSAria) was used to isolate blast cells according to leukemic blast immunophenotype before DNA isolation.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > EXPERIMENTAL PROCEDURES > Sequence Analysis of IDH1 and IDH2
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Wild-type and mutant sequences were then subcloned into pcDNA3 (Invitrogen) and confirmed by direct sequencing before expression in mammalian cells.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > EXPERIMENTAL PROCEDURES > Constructing IDH1 and IDH2 mutants
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All DNA samples were whole genome amplified using Ø29 polymerase and mutations were validated on unamplified DNA to ensure all mutations were present in the diagnostic sample.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > EXPERIMENTAL PROCEDURES > Sequence Analysis of IDH1 and IDH2
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Sequence analysis was performed using Mutation Surveyor (SoftGenetics, State College PA) and all mutations were validated by repeat PCR and sequencing on unamplified DNA from the archival sample.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > EXPERIMENTAL PROCEDURES > Sequence Analysis of IDH1 and IDH2
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“Mitochondria typically have a high NADPH/NADP+ ratio, supported in part by the ability to interconvert NADPH and NADH in the matrix (Rydstrom, 2006).”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > DISCUSSION > Maintaining at least one IDH1 and IDH2 wild-type allele may be essential for transformed cells
What the sources say
- Not checked yetcites Rydstrom, 2006 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
All reported IDH1 or IDH2 mutations are heterozygous, with cancer cells retaining one wild-type copy of the relevant allele.
“To date, all reported IDH1 or IDH2 mutations are heterozygous, with the cancer cells retaining one wild-type copy of the relevant IDH1 or IDH2 allele”
The paper relies on this without support.
No patient has been reported with both an IDH1 and IDH2 mutation.
“No patient has been reported with both an IDH1 and IDH2 mutation”
The paper relies on this without support.
All reported IDH1 mutations result in an amino acid substitution at a single arginine residue in the enzyme's active site, R132.
“To date, all reported IDH1 mutations result in an amino acid substitution at a single arginine residue in the enzyme’s active site, R132”
The paper relies on this without support.
IDH2 mutations identified in gliomas occur at the analogous residue to IDH1 R132, IDH2 R172.
“The IDH2 mutations which have been identified in gliomas occur at the analogous residue to IDH1 R132, IDH2 R172”
The paper relies on this without support.
IDH1 contributes to cytosolic NADPH production.
“IDH1 contributes to cytosolic NADPH production.”
The paper relies on this without support.
Mitochondrial α-ketoglutarate levels are kept high by various anaplerotic substrates.
“In addition, mitochondrial α-ketoglutarate is maintained at high levels by a variety of anaplerotic substrates.”
The paper relies on this without support.
IDH mutations occur frequently in gliomas with mixed astrocytic and oligodendroglial features and in acute myeloid leukemias.
“a possibility by which 2HG might contribute to tumorigenesis emerges from consideration of the tumor subtypes in which IDH mutations are found with high frequency: gliomas with mixed astrocytic and oligodendroglial features, and acute myeloid leukemias.”
The paper relies on this without support.
In those two tumor types, disease centers on proliferation of relatively undifferentiated cells, and pathogenesis involves a differentiation block rather than only faster proliferation.
“In both cases, proliferation of a relatively undifferentiated cell population is central to the disease, and pathogenesis is marked by a block to differentiation rather than simply by an increase in proliferative rate.”
The paper relies on this without support.
Most enzyme mutations linked to cancer cause either loss of catalysis or constitutive activation.
“Most cancer-associated enzyme mutations result in either catalytic inactivation or constitutive activation.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, 2-HG acts as a competitive inhibitor of α-KG, and its production by mutant IDH1 consumes α-KG (81, 99), leading to reduced TET2 and JmjC activity in tumor cells (79, 80).”
From Fueling Immunity: Insights into Metabolism and Lymphocyte Function (2013) · cites this paper as [99]
Experimental — accuracy not yet measuredIn the citing paper
“Wild-type IDH1 and IDH2 catalyze the reversible oxidative decarboxylation of isocitrate to alpha-ketoglutarate (αKG) and CO2 (Figure 4a). Cancer associated mutations in IDH1 and IDH2 eliminate this function and confer a neomorphic activity to the enzyme, generating D-2-hydroxyglutarate (D-2HG) via the reduction of αKG (Figure 4b)(Dang et al., 2009; Ward et al., 2010).”
From Targeting Metabolism for Cancer Therapy (2017) · cites this paper as Ward et al., 2010
In the citing paper
“Thus, various tumors, including glioma, secondary glioblastoma, and acute myeloid leukemia (AML), harboring heterozygous point mutations in the active sites of IDH1/2 show dramatic increases in the R-2-HG levels111,113–115.”
From Glutamine reliance in cell metabolism (2020) · cites this paper as [113]
In the citing paper
“The high concentrations of R-2HG (more than 10 mM) that have been observed in malignant brain tumours and leukaemias (Dang et al, 2009;Gross et al, 2010;Ward et al, 2010), might be sufficient to inhibit even the less-susceptible 2OG oxygenases.”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Ward et al, 2010
In the citing paper
“As production of 2HG by IDH mutations is stereospecific (Dang et al, 2009;Ward et al, 2010), the specificity of inhibition by the 2HG enantiomers is relevant to their potential as mediators of oncogenic pathways.”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Ward et al, 2010
In the citing paper
“However, they also cause a gain of function comprising catalysis of 2OG to the R-enantiomer of 2-hydroxyglutarate (R-2HG; Dang et al, 2009;Gross et al, 2010;Ward et al, 2010).”
From The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases (2011) · cites this paper as Ward et al, 2010
In the citing paper
“Tumor-associated IDH mutations unmask a latent ability of these enzymes to produce the R enantiomer of 2-hydroxyglutarate, which accumulates to low millimolar levels in IDH mutant tumors (Dang et al., 2009; Gross et al., 2010; Ward et al., 2010).”
From Influence of Metabolism on Epigenetics and Disease (2013) · cites this paper as Ward et al., 2010
In the citing paper
“Oncogenic mutations in genes encoding IDH1/2 result in neomorphic enzyme activity that favors reduction of αKG to d-2-hydroxyglutarate (D-2HG) (167, 168).”
From Regulation and function of the mammalian tricarboxylic acid cycle (2023) · cites this paper as [168]
In the citing paper
“In contrast to wild-type isocitrate dehydrogenases, which convert the TCA cycle metabolite isocitrate to α-ketoglutarate, a mutant form of IDH prefers to use α-ketoglutarate as a substrate, catalyzing its conversion to the D-enantiomer of 2-hydroxyglutarate (2-HG) (Dang et al., 2010; Ward et al., 2010).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Ward et al., 2010
In the citing paper
“the common feature of this remaining subset of 2HG-elevated AMLs was another mutation in IDH2, occurring at R140 (Ward et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Ward et al., 2010
In the citing paper
“Enzymatic assays and measurement of 2HG levels in primary AML samples confirmed that these IDH2 R172 mutations result in 2HG elevation (Gross et al., 2010; Ward et al., 2010).”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Ward et al., 2010
In the citing paper
“some 2HG-elevated AML samples lacked IDH1 R132 or IDH2 R172 mutations”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Ward et al., 2010
In the citing paper
“has been investigated since then as a way to produce citrate and fatty acids from α-ketoglutarate derived from glutamine (Holleran et al., 1995; Ward et al., 2010; Yoo et al., 2008)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Ward et al., 2010
In the citing paper
“R(-)-2HG (also known as D-2HG) is the exclusive 2HG stereoisomer produced by IDH1 and IDH2 mutants (Dang et al., 2009; Ward et al., 2010)”
From Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate (2012) · cites this paper as Ward et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > DISCUSSION > Maintaining at least one IDH1 and IDH2 wild-type allele may be essential for transformed cells
“Nevertheless, both mutant proteins lead to an over 100-fold increase in tumor 2HG accumulation.”
§ The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzymatic activity that converts α-ketoglutarate to 2-hydroxyglutarate > DISCUSSION > 2HG as a screening and diagnostic marker
“The 2HG levels in cancers with IDH mutations are consistently 10–100 fold elevated over levels found in samples lacking mutations of IDH1 or IDH2.”
Citations
Cites
The PyMOL Molecular Graphics System
DeLano, W. L. (2002) · Medical Entomology and Zoology · Cited by 18,147
IDH1 and IDH2 Mutations in Gliomas
Yan, H., Parsons, D. W., Jin, G., McLendon, R., Rasheed, B. A., Yuan, W., Kos, I., Batinic-Haberle, I., Jones, S., Riggins, G. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808710 · Cited by 5,847
Cancer-associated IDH1 mutations produce 2-hydroxyglutarate
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M., Fantin, V. R., Jang, H. G., Jin, S., Keenan, M. C., et al. (2009) · Nature · doi:10.1038/nature08617 · Cited by 4,154
Self-citationThe Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D. L., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,161 · cited 1×
“Mutations have also been reported in cancers of the colon and prostate (Kang et al., 2009; Sjoblom et al., 2006).”
BackgroundDeBerardinis, R. J., Mancuso, A., Daikhin, E., Nissim, I., Yudkoff, M., Wehrli, S., & Thompson, C. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709747104 · Cited by 2,622 · cited 1×
“IDH1 is one of only three cytosolic enzymes that contribute to the NADPH production required for nucleotide and lipid biosynthesis during cell growth (DeBerardinis et al., 2007).”
BackgroundSelf-citationRecurring mutations found by sequencing an acute myeloid leukemia genome
Mardis, E. R., Ding, L., Dooling, D. J., Larson, D. E., McLellan, M. D., Chen, K., Koboldt, D. C., Fulton, R. S., Delehaunty, K. D., McGrath, S. D., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0903840 · Cited by 2,219
Hartmann, C. J., Meyer, J., Balß, J., Capper, D., Mueller, W. C., Christians, A., Felsberg, J., Wolter, M., Mawrin, C., Wick, W., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0561-9 · Cited by 1,163 · cited 1×
“This is in contrast to the data reported for gliomas in which less than 5% of IDH mutations were in IDH2 (Hartmann et al., 2009; Yan et al., 2009).”
ResultGlioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Zhao, S., Lin, Y., Xu, W., Jiang, W., Zha, Z., Wang, P., Yu, W., Li, Z., Gong, L., Peng, Y., et al. (2009) · Science · doi:10.1126/science.1170944 · Cited by 1,119 · cited 1×
“Therefore, it has been proposed that mutant IDH1 can act as a dominant negative against wild-type IDH1 function, resulting in a decrease in cytosolic a-ketoglutarate levels and leading to an indirect activation of the HIF-1a pathway (Zhao et al., 2009).”
BackgroundBajad, S. U., Lu, W., Kimball, E., Yuan, J., Peterson, C. N., & Rabinowitz, J. D. (2006) · Journal of Chromatography A · doi:10.1016/j.chroma.2006.05.019 · Cited by 593 · cited 1×
“Reactions used to monitor other TCA components have been described previously (Bajad et al., 2006).”
MethodSelf-citationAnalytical strategies for LC–MS-based targeted metabolomics
Lu, W., Bennett, B. D., & Rabinowitz, J. D. (2008) · Journal of Chromatography B · doi:10.1016/j.jchromb.2008.04.031 · Cited by 489 · cited 1×
“In both cases, LC separation was by reversed phase chromatography using tributylamine as an ion pairing agent (Lu et al., 2008; Luo et al., 2007) with ionization by negative electrospray at 23 kV.”
MethodSelf-citation
Cited by
Sorted by citations
Items 801–900 of 1,003
Exogenous Gene Transmission of Isocitrate Dehydrogenase 2 Mimics Ischemic Preconditioning Protection
Kolb, A. L., Corridon, P. R., Zhang, S., Xu, W., Witzmann, F. A., Collett, J. A., Rhodes, G. J., Winfree, S., Bready, D., Pfeffenberger, Z. J., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017060675 · Cited by 32
Sepsa, A., Levidou, G., Gargalionis, A. N., Adamopoulos, C., Spyropoulou, A., Dalagiorgou, G., Thymara, I., Boviatsis, E. I., Themistocleous, M. S., Petraki, K., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0115101 · Cited by 41
Reductive carboxylation and 2-hydroxyglutarate formation by wild-type IDH2 in breast carcinoma cells
Smolková, K., Dvořák, A., Zelenka, J., Vı́tek, L., & Ježek, P. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.05.012 · Cited by 39
Molecular targeting in acute myeloid leukemia
Lim, S. H., Dubielecka, P. M., & Raghunathan, V. M. (2017) · Journal of Translational Medicine · doi:10.1186/s12967-017-1281-x · Cited by 43
Metabolism, Epigenetics, and Causal Inference in Heart Failure
Kimball, T. H., & Vondriska, T. M. (2019) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2019.11.009 · Cited by 40
IDH mutations in liver cell plasticity and biliary cancer
Saha, S. K., Parachoniak, C. A., & Bardeesy, N. M. (2014) · Cell Cycle · doi:10.4161/15384101.2014.965054 · Cited by 46
Molecular Pathways: IDH2 Mutations—Co-opting Cellular Metabolism for Malignant Transformation
Stein, E. M. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0362 · Cited by 40
Intraoperative tissue identification by mass spectrometric technologies
John, E. S., Rossi, M., Pruski, P., et al. (2016) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2016.05.003 · Cited by 42
RNA-Based Fluorescent Biosensors for Detecting Metabolites in vitro and in Living Cells
Jaffrey, S. R. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.09.005 · Cited by 39
Karigane, D., & Takubo, K. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2261-x · Cited by 40
Ferret, Y., Boissel, N., Hélevaut, N., Madic, J., Nibourel, O., Marceau‐Renaut, A., Bucci, M., Geffroy, S., Celli‐Lebras, K., Castaigné, S., et al. (2018) · Haematologica · doi:10.3324/haematol.2017.183525 · Cited by 45
Mutation matters in precision medicine: A future to believe in
Dey, N., Williams, C. B., Leyland-Jones, B. R., & De, P. K. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.03.002 · Cited by 41
Dnmt3a loss and Idh2 neomorphic mutations mutually potentiate malignant hematopoiesis
Zhang, X., Wang, X., Wang, X. Q. D., Su, J., Putluri, N., Zhou, T., Qu, Y., Jeong, M., Guzman, A. G., Rosas, C., et al. (2020) · Blood · doi:10.1182/blood.2019003330 · Cited by 44
The remodel of the “central dogma”: a metabolomics interaction perspective
dos Santos, G. C., Renovato‐Martins, M., & de Brito, N. M. (2021) · Metabolomics · doi:10.1007/s11306-021-01800-8 · Cited by 48
Bruno, S., Mancini, M., Santis, S. D., Monaldi, C., Cavo, M., & Soverini, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136857 · Cited by 43
Jha, P., Suri, V. S., Sharma, V., Singh, G., Sharma, M. C., Pathak, P., Chosdol, K., Jha, P., Suri, A., Mahapatra, A. K., et al. (2011) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2011.04.017 · Cited by 42
Stem cell origin of myelodysplastic syndromes
Elias, H. K., Schinke, C., Bhattacharyya, S., Will, B., Verma, A. K., & Steidl, U. G. (2013) · Oncogene · doi:10.1038/onc.2013.520 · Cited by 40
Zou, Y., Zeng, Y., Zhang, D., Zou, S., Cheng, Y., & Yao, Y. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.10.038 · Cited by 42
TET proteins in cancer: Current ‘state of the art’
Rawłuszko-Wieczorek, A. A., Siera, A., & Jagodziński, P. P. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.07.008 · Cited by 40
Altered expression levels of IDH2 are involved in the development of colon cancer
LV, Q., Xing, S., LI, Z., Li, J., Gong, P., Xu, X., CHANG, L., Jin, X., Gao, F., Li, W., et al. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.676 · Cited by 38
Jaramillo, S., & Schlenk, R. F. (2023) · Haematologica · doi:10.3324/haematol.2022.280802 · Cited by 44
Enasidenib and ivosidenib in AML
Martelli, M. P., Martino, G., Cardinali, V., Falini, B., Martinelli, G., & Cerchione, C. (2020) · Minerva Medica · doi:10.23736/s0026-4806.20.07024-x · Cited by 42
Liu, W., Chan, S., Chang, H., Li, G., Tu, Y.-T., Tseng, H., Fu, T., Chang, H.-Y., Liou, H., Ger, L., et al. (2018) · Breast Cancer Research · doi:10.1186/s13058-018-0953-7 · Cited by 40
Lazović, J., Soto, H., Piccioni, D. E., Ru, J. R. L., Li, S., Mirsadraei, L., Yong, W. H., Prins, R. M., Liau, L. M., Ellingson, B. M., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos258 · Cited by 42
Glutamine Metabolism: Molecular Regulation, Biological Functions, and Diseases
Kumar, M. A., Baba, S. K., Khan, I. R., Khan, M. S., Husain, F. M., Ahmad, S., Haris, M., Singh, M., Akil, A. A., Macha, M. A., et al. (2025) · MedComm · doi:10.1002/mco2.70120 · Cited by 52
Kim, H. J., Kim, S. H., Cha, H., Kim, S. R., Lee, J. H., & Park, J. (2016) · Free Radical Research · doi:10.1080/10715762.2016.1185519 · Cited by 39
Advances in Epigenetic Cancer Therapeutics
Hillyar, C., Rallis, K. S., & Varghese, J. S. (2020) · Cureus · doi:10.7759/cureus.11725 · Cited by 40
Chen, Z., Ioris, R. M., Richardson, S., Van Ess, A. N., Vendrell, I., Kessler, B. M., Buffa, F. M., Busino, L., Clifford, S. C., Bullock, A. N., et al. (2022) · Cell Death & Differentiation · doi:10.1038/s41418-022-00983-4 · Cited by 41
Mitochondrial 2-hydroxyglutarate metabolism
Engqvist, M. K. M., Eßer, C., Maier, A., Lercher, M. J., & Maurino, V. G. (2014) · Mitochondrion · doi:10.1016/j.mito.2014.02.009 · Cited by 46
An, Z., Tiwari, V., Ganji, S., Baxter, J. D., Levy, M. L., Pinho, M. C., Pan, E., Maher, E. A., Patel, T., Mickey, B., et al. (2017) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26884 · Cited by 35
The Time Has Come for Targeted Therapies for AML: Lights and Shadows
Fiorentini, A., Capelli, D., Saraceni, F., Menotti, D., Poloni, A., & Olivieri, A. (2020) · Oncology and Therapy · doi:10.1007/s40487-019-00108-x · Cited by 35
2-hydroxyglutarate inhibits MyoD-mediated differentiation by preventing H3K9 demethylation
Schvartzman, J. M., Reuter, V. P., Koche, R. P., & Thompson, C. B. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1817662116 · Cited by 43
Self-citationClinical development of IDH1 inhibitors for cancer therapy
Zarei, M., Hue, J. J., Hajihassani, O., Graor, H. J., Katayama, E., Loftus, A. W., Bajor, D. L., Rothermel, L. D., Gohar, A. V., & Winter, J. M. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102334 · Cited by 39
Malic enzyme 2 maintains protein stability of mutant p53 through 2-hydroxyglutarate
Zhao, M., Yao, P., Mao, Y., Wu, J., Wang, W., Geng, C., Cheng, J., Du, W., & Jiang, P. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00532-w · Cited by 40
Lyle, M. R., Dolia, J. N., Fratkin, J. F., et al. (2015) · Child Neurology Open · doi:10.1177/2329048x14567531 · Cited by 40
Pisapia, D. J. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2016-0493-ra · Cited by 43
Molecular profiling of gliomas: potential therapeutic implications
Alentorn, A., Durán-Peña, A., Pingle, S. C., Piccioni, D. E., Idbaïh, A., & Kesari, S. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1062368 · Cited by 33
Gerometabolites: The pseudohypoxic aging side of cancer oncometabolites
Menéndez, J. A., Alarcón, T., & Joven, J. (2014) · Cell Cycle · doi:10.4161/cc.28079 · Cited by 42
Jones, S. D., Ahmet, J., Ayton, K., Ball, M. D., Cockerill, M. J., Fairweather, E. E., Hamilton, N. S., Harper, P., Hitchin, J. R., Jordan, A. M., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01320 · Cited by 42
Metabolic underpinnings of leukemia pathology and treatment
Nemkov, T. G., D’Alessandro, A., & Reisz, J. A. (2018) · Cancer Reports · doi:10.1002/cnr2.1139 · Cited by 46
Kelly, A. D., Kroeger, H., Yamazaki, J., Taby, R. F., Neumann, F., Yu, S., Lee, J. T., Patel, B. G., Li, Y. C., He, R. L., et al. (2017) · Leukemia · doi:10.1038/leu.2017.12 · Cited by 40
Rapid diagnosis of IDH1-mutated gliomas by 2-HG detection with gas chromatography mass spectrometry
Xu, H., Xia, Y., Li, C., Zhang, J., Liu, Y., Wei, Y., Qin, Z., Chen, L., Shi, Z., Quan, K., et al. (2018) · Laboratory Investigation · doi:10.1038/s41374-018-0163-z · Cited by 32
Simonetti, G., Mengucci, C., Padella, A., Fonzi, E., Picone, G., Delpino, C., Nanni, J., Tommaso, R. D., Franchini, E., Papayannidis, C., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01318-x · Cited by 40
Chapuis, N., Poulain, L., Birsen, R., Tamburini, J., & Bouscary, D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00405 · Cited by 48
Poinsignon, V., Mercier, L., Nakabayashi, K., David, M. D., Lalli, A., Penard‐Lacronique, V., Quivoron, C., Saada, V., de Botton, S., Broutin, S., et al. (2016) · Journal of Chromatography B · doi:10.1016/j.jchromb.2016.04.030 · Cited by 43
New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP
Mhaidly, R., Krug, A., Gaulard, P., Lemonnier, F., Ricci, J., & Verhoeyen, E. (2020) · Oncogenesis · doi:10.1038/s41389-020-00259-x · Cited by 39
Cancer metabolism and dietary interventions
Qian, L., Zhang, F., Yin, M., & Lei, Q. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2021.0461 · Cited by 40
Molecular Targets in Glioblastoma
Zorzan, M., Giordan, E., Redaelli, M., Caretta, A., & Mucignat‐Caretta, C. (2015) · Future Oncology · doi:10.2217/fon.15.22 · Cited by 38
Metabolic regulation of the glioblastoma stem cell epitranscriptome by malate dehydrogenase 2
Lv, D., Dixit, D., Cruz, A. F., Kim, L. J. Y., Duan, L., Xu, X. Y., Wu, Q., Zhong, C., Lu, C., Gersey, Z. C., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.09.014 · Cited by 47
Targeting IDH1 and IDH2 Mutations in Acute Myeloid Leukemia
Ragon, B. K., & Dinardo, C. D. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0418-6 · Cited by 39
Tissue-Based Metabolomics to Analyze the Breast Cancer Metabolome
Budczies, J., & Denkert, C. (2016) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-319-42118-6_7 · Cited by 39
Advances into understanding metabolites as signaling molecules in cancer progression
Liu, J. Y., & Wellen, K. E. (2020) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2020.01.013 · Cited by 38
The Genetics of Myelodysplastic Syndromes: Clinical Relevance
Chiereghin, C., Travaglino, E., Zampini, M., Saba, E., Saitta, C., Riva, E., Bersanelli, M., & Porta, M. G. D. (2021) · Genes · doi:10.3390/genes12081144 · Cited by 42
Development and Maintenance of Cancer Stem Cells under Chronic Inflammation
Tanno, T., & Matsui, W. H. (2011) · Journal of Nippon Medical School · doi:10.1272/jnms.78.138 · Cited by 39
The metabolic adaptation mechanism of metastatic organotropism
Wang, C., & Luo, D. (2021) · Experimental Hematology and Oncology · doi:10.1186/s40164-021-00223-4 · Cited by 40
IDH Signalling Pathway in Cholangiocarcinoma: From Biological Rationale to Therapeutic Targeting
Salati, M., Caputo, F., Baldessari, C., Galassi, B., Grossi, F., Dominici, M., & Ghidini, M. (2020) · Cancers · doi:10.3390/cancers12113310 · Cited by 42
Detection of 2‐hydroxyglutarate in brain tumors by triple‐refocusing MR spectroscopy at 3T in vivo
An, Z., Ganji, S., Tiwari, V., Pinho, M. C., Patel, T., Barnett, S. L., Pan, E., Mickey, B., Maher, E. A., & Choi, C. (2016) · Magnetic Resonance in Medicine · doi:10.1002/mrm.26347 · Cited by 38
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System
Nieto‐Sampedro, M., Valle‐Argos, B., Gómez‐Nicola, D., Fernández‐Mayoralas, A., & Nieto‐Díaz, M. (2011) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s7685 · Cited by 39
Rational design of a turn-on fluorescent sensor for α-ketoglutaric acid in a microfluidic chip
Jin, P., Jiao, C., Guo, Z., He, Y., Zhu, S., Tian, H., & Zhu, W. (2014) · Chemical Science · doi:10.1039/c4sc01378f · Cited by 38
Schaefer, I., Hornick, J. L., & Bovée, J. V. M. G. (2018) · Laboratory Investigation · doi:10.1038/s41374-017-0003-6 · Cited by 36
Cormio, A., Sanguedolce, F., Musicco, C., Pesce, V., Calò, G., Bufo, P., Carrieri, G., & Cormio, L. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.07.001 · Cited by 33
Grassi, S., Guerrini, F., Ciabatti, E., Puccetti, R., Salehzadeh, S., Metelli, M. R., Vita, A. D., Domenichini, C., Caracciolo, F., Orciuolo, E., et al. (2020) · Cancers · doi:10.3390/cancers12071738 · Cited by 35
Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer
Guo, J., Zhang, R., Yang, Z., Duan, Z., Yin, D.-T., & Zhou, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.644857 · Cited by 36
Falini, B., Sportoletti, P., Brunetti, L., & Martelli, M. P. (2015) · British Journal of Haematology · doi:10.1111/bjh.13409 · Cited by 38
Current understanding of the human microbiome in glioma
Liang, J., Li, T., Zhao, J., Wang, C., & Sun, H. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.781741 · Cited by 37
Oizel, K., Gratas, C., Nadaradjane, A., Oliver, L., Vallette, F. M., & Pecqueur, C. (2015) · Cell Death and Disease · doi:10.1038/cddis.2015.13 · Cited by 38
The origins and functional effects of postzygotic mutations throughout the human life span
Rockweiler, N. B., Ramu, A., Nagirnaja, L., Wong, W., Noordam, M. J., Drubin, C. W., Huang, N., Miller, B., Todres, E. Z., Vigh‐Conrad, K. A., et al. (2023) · Science · doi:10.1126/science.abn7113 · Cited by 39
Molecular prognostic factors in cytogenetically normal acute myeloid leukemia
Walker, A., & Marcucci, G. (2012) · Expert Review of Hematology · doi:10.1586/ehm.12.45 · Cited by 39
Damm, F., Bunke, T., Thol, F. R., Markus, B., Wagner, K., Göhring, G., Schlegelberger, B., Heil, G., Reuter, C. W., Püellmann, K., et al. (2011) · Leukemia · doi:10.1038/leu.2011.200 · Cited by 37
Non-Conventional Treatments for Conventional Chondrosarcoma
Monga, V., Mani, H., Hirbe, A. C., & Milhem, M. M. (2020) · Cancers · doi:10.3390/cancers12071962 · Cited by 38
Novel therapeutic options in Acute Myeloid Leukemia
Medinger, M., Lengerke, C., & Passweg, J. R. (2016) · Leukemia Research Reports · doi:10.1016/j.lrr.2016.09.001 · Cited by 36
Kennedy, C. R., Tilkens, S. B., Guan, H., Garner, J. A., Or, P. M. Y., & Chan, A. M.-L. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.020 · Cited by 38
Kim, J. Y., Heo, S., Choi, S. K., Song, I. H., Park, I. A., Kim, Y., Park, H. S., Park, S. Y., Bang, W. S., Gong, G., et al. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2083-5 · Cited by 36
Genomics and Therapeutic Vulnerabilities of Primary Bone Tumors
Scotlandi, K., Hattinger, C. M., Pellegrini, E., Gambarotti, M., & Serra, M. (2020) · Cells · doi:10.3390/cells9040968 · Cited by 41
Bruserud, Ø., Aasebø, E., Hernandez-Valladares, M., Tsykunova, G., & Reikvam, H. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1356818 · Cited by 38
IGFBP2 expression predicts IDH-mutant glioma patient survival
Huang, L. E., Cohen, A. L., Colman, H., Jensen, R. L., Fults, D. W., & Couldwell, W. T. (2016) · Oncotarget · doi:10.18632/oncotarget.13329 · Cited by 37
Novel therapies for AML: a round-up for clinicians
Swaminathan, M., & Wang, E. S. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1850255 · Cited by 36
Miyata, S., Tominaga, K., Sakashita, E., Urabe, M., Onuki, Y., Gomi, A., Yamaguchi, T., Mieno, M., Mizukami, H., Kume, A., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-46217-5 · Cited by 33
Targeting the IDH2 Pathway in Acute Myeloid Leukemia
Amaya, M. L., & Pollyea, D. A. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0536 · Cited by 37
Inborn errors of metabolite repair
Veiga‐da‐Cunha, M., SCHAFTINGEN, E. V., & Bommer, G. T. (2019) · Journal of Inherited Metabolic Disease · doi:10.1002/jimd.12187 · Cited by 34
A d-2-hydroxyglutarate biosensor based on specific transcriptional regulator DhdR
Xiao, D., Zhang, W., Guo, X., Liu, Y., Hu, C., Guo, S., Kang, Z., Xu, X., Ma, C., Gao, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27357-7 · Cited by 34
Lage, L. A. D. P. C., Culler, H. F., Reichert, C. O., Siqueira, S. A. C., & Pereira, J. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1177590 · Cited by 37
Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia.
Medinger, M., Lengerke, C., & Passweg, J. R. (2016) · Europe PMC (PubMed Central) · Cited by 36
Papillary thyroid carcinoma shows elevated levels of 2-hydroxyglutarate
Rakheja, D., Boriack, R. L., Mitui, M., Khokhar, S., Holt, S. A., & Kapur, P. (2010) · Tumor Biology · doi:10.1007/s13277-010-0125-6 · Cited by 37
Adaptions to Hypoxia and Redox Stress
Loscalzo, J. (2016) · Circulation Research · doi:10.1161/circresaha.116.309394 · Cited by 34
Essential Role of Nonessential Amino Acid Glutamine in Atherosclerotic Cardiovascular Disease
Chen, J., Zhang, S., Wu, J., Wu, S., Xu, G., & Wei, D. (2019) · DNA and Cell Biology · doi:10.1089/dna.2019.5034 · Cited by 37
Kim, H., Kim, S., Lee, H. H., & Heo, H. (2016) · Korean Journal of Radiology · doi:10.3348/kjr.2016.17.5.620 · Cited by 36
The metabolomic signature of hematologic malignancies
Allegra, A., Innao, V., Gerace, D. G., Bianco, O., & Musolino, C. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.08.002 · Cited by 32
Mechanisms of Epigenetic Regulation of Leukemia Onset and Progression
Ntziachristos, P., Mullenders, J., Trimarchi, T., & Aifantis, I. (2013) · Advances in immunology · doi:10.1016/b978-0-12-410524-9.00001-3 · Cited by 37
Metabo-Devo: A metabolic perspective of development
Gándara, L., & Wappner, P. (2018) · Mechanisms of Development · doi:10.1016/j.mod.2018.02.004 · Cited by 31
Bianconi, A., Palmieri, G., Aruta, G., Monticelli, M., Zeppa, P., Tartara, F., Melcarne, A., Garbossa, D., & Cofano, F. (2023) · Biomedicines · doi:10.3390/biomedicines11061520 · Cited by 35
Li, S., Li, W., Yuan, J., Bullova, P., Wu, J., Zhang, X., Liu, Y., Plescher, M., Rodríguez, J., Bedoya-Reina, O. C., et al. (2022) · Nature Metabolism · doi:10.1038/s42255-022-00593-x · Cited by 36
Role of LncRNAs in regulating cancer amino acid metabolism
Guo, Y., Lv, B., Liu, R., Dai, Z., Zhang, F., Liang, Y., Yu, B., Zeng, D., Lv, X., & Zhang, Z. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01926-8 · Cited by 35
Platt, M. Y., Fathi, A. T., Borger, D. R., Brunner, A. M., Hasserjian, R. P., Balaj, L., Lum, A. M., Yip, S. S. F., Dias-Santagata, D. C., Zheng, Z., et al. (2015) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2015.06.004 · Cited by 36
Bill, M., Jentzsch, M., Bischof, L., Kohlschmidt, J., Grimm, J., Schmalbrock, L. K., Backhaus, D., Brauer, D., Goldmann, K., Franke, G., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005789 · Cited by 35
Shao, J., Shi, T., Yu, H. T., Ding, Y., Li, L., Wang, X., & Wang, X. (2021) · The EMBO Journal · doi:10.15252/embj.2020107480 · Cited by 30
A pharmacogenomic approach validates AG-221 as an effective and on-target therapy in IDH2 mutant AML
Kats, L. M., Vervoort, S. J., Cole, R., Rogers, A. J., Gregory, G. P., Vidacs, E., Li, J., Nagaraja, R., Yen, K. E., & Johnstone, R. W. (2017) · Leukemia · doi:10.1038/leu.2017.84 · Cited by 31
Take Advantage of Glutamine Anaplerosis, the Kernel of the Metabolic Rewiring in Malignant Gliomas
Martins, F., Gonçalves, L. G., Pojo, M., & Serpa, J. (2020) · Biomolecules · doi:10.3390/biom10101370 · Cited by 35
Warburg and Krebs and related effects in cancer
Unterlass, J. E., & Curtin, N. J. (2019) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2019.4 · Cited by 35
Metadata
- Authors
- Ward, P. S., Patel, J., Wise, D. R., Abdel-Wahab, O., Bennett, B. D., Coller, H. A., Cross, J. R., Fantin, V. R., Hedvat, C. V., Perl, A. E., Rabinowitz, J. D., Carroll, M., Su, S. M., Sharp, K. A., Levine, R. L., & Thompson, C. B.
- Affiliations
- Abramson Cancer Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- Princeton University (US)
- Agios Pharmaceuticals (United States) (US)
- University of Pennsylvania (US)
- Corresponding author
- Thompson, Craig B.
- ORCID
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-03
- Volume
- 17
- Issue
- 3
- Pages
- 225-234
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2849316
- OpenAlex
- W1995675594
- Cited by
- 2,020
- References
- 27
- Citations by year
- 2026: 76 · 2025: 68 · 2024: 113 · 2023: 102 · 2022: 111 · 2021: 149 · 2020: 137 · 2019: 148 · 2018: 133 · 2017: 127 · 2016: 151 · 2015: 140 · 2014: 110 · 2013: 126 · 2012: 126
- FWCI
- 90.68
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Howard Hughes Medical Institute
- University of Pennsylvania
- Memorial Sloan-Kettering Cancer Center
- Agios Pharmaceuticals
- National Cancer Institute (P01CA104838, R01CA092660, R01CA105463)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- IDH1 mutation, IDH2 mutation, 2-hydroxyglutarate, acute myeloid leukemia, oncometabolites, alpha-ketoglutarate, isocitrate dehydrogenase, chromosomal abnormalities, glioma
- MeSH terms
- Glutarates, Humans, Isocitrate Dehydrogenase, Isocitrates, Ketoglutaric Acids, Mitochondria, Mutation, Tumor Cells, Cultured, Leukemia, Myeloid, Acute, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
